Directorate-general Curative Care
Director-General: Bas van den Dungen
Medical care, health and social insurance system, pharmaceuticals and medical aids
Curative Care Department (CZ)
Director: drs. M.C. Beens (Marije)
CZ is responsible, from the perspective of health care providers, for the design and functioning of the care system with the aim of promoting general quality of life.
- Secondary Care (TSZ)
- Primary and Integrated Care (EKZ)
- Financial Policy and Information (FBI)
- Mental Health Care (CGGZ)
Pharmaceuticals and Medical Technology Department (GMT)
Director: dr. M.T.M. (Marcel) van Raaij
Pharmaceuticals, medical devices, blood products, human tissue and organs, and radiotherapy are all crucially important healthcare products. The government has a special responsibility in this respect to provide care efficiently by ensuring good-quality, safe products. The task of GMT is:
'To ensure access to and effective use of sound, safe medical products that meet current requirements, at a socially acceptable cost.'
GMT works at the interface between powerful commercial and public interests, and scientific advances. Stakeholders in this field are the public, health insurers, healthcare providers, doctors, chemists, manufacturers, wholesalers, scientists, national and international organisations, advisory bodies and implementing bodies, and Dutch and European policymakers. Clearly, where so many players are involved, careful consideration needs to be given to all interests. GMT ensures that this is done.
- Innovation and Availability of Medical Products (GMT/IB)
- Market Authorisation and Safe Use of Medical Products (GMT/MVG)
- Payment for and Effective Use of Medical Products (GMT/VDG)
Market and Consumer Affairs Department
Director: Fred Krapels
The Market and Consumer Affairs Department (MC) works to ensure a strong position for those who need care, and creates a framework in which care providers are accountable and have space in which to operate. To this end it makes policy that is geared to prevention, cure and long-term care.
- optimising the legal position of healthcare clients/patients through the new Patients’ Rights (Care Sector) Act (WCZ);
- maintaining relations with interest groups representing patients, the disabled and the elderly, including through grants;
- drawing up policy to ensure good governance of organisations (also through the WCZ). At issue here are the relationship between management and supervisory boards and the relationship between supervisory boards and professionals (including medical specialists). The size of institutions (including mergers) falls under good governance;
- determining the arena in which care institutions operate through policy relating to market organisation and the funding of care. MC shapes such policy for both medical and long-term care through the Market Organisation (Health Care) Act;
- coordinating ministerial policy on quality. Transparency and the provision of information are an important part of this, being achieved through such instruments as the Visible Care Programme, a website enabling consumers to compare care providers, the annual Social Accountability report and the development of indicators;
- contributing to the development of the new institute for the quality of care;
- drawing up policy on market supervision;
- acting as account holder for various non-departmental agencies in the care sector: the Dutch Healthcare Authority, the Care Institutions (Building Projects) Board and the Healthcare Organisations (Termination and Mergers) Board.
- Fred Krapels: director;
- Brigitte Zonneveld: member MT, acting director;
- Goof Buijs: member MT;
- Conny Wijnants: secretary.